Cardiac biomarkers response under angiotensin receptor–neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study
Open Access
- 3 March 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (2)
Abstract
Introduction: Natriuretic peptides (NPs) are central to the diagnostic and therapeutic management of heart failure (HF), yet their short-term dynamics under sacubitril/valsartan (S/V) therapy and during acute volume changes remain incompletely characterized. We aimed to assess changes in circulating biomarkers and response to standardized acute intravascular volume expansion and diuretic treatment before and after S/V initiation. Methods: We studied 229 ambulatory patients with HF with reduced ejection fraction receiving guideline-directed medical therapy who initiated S/V. Patients were evaluated at three outpatient visits: before S/V initiation and after 2 and 3 months of treatment. At each visit, participants underwent a standardized 9-hour protocol including volume infusion followed by diuretic administration. BNP, NT-proBNP, MR-proANP, and neprilysin activity were measured serially alongside clinical assessment and natriuresis. Results: Across visits, initiation of S/V was associated with lower concentrations of BNP (−8%, P = .009) and NT-proBNP (−35%, P < .001). During the acute protocol, both BNP and NT-proBNP increased significantly over time (timepoint effect P < .001), with parallel trajectories before and after S/V initiation and no visit-by-time interaction (P = .17 for BNP; P = .95 for NT-proBNP). Despite marked natriuresis and improvement in clinical signs following diuretic administration, BNP and NT-proBNP continued to rise during the 9-hour observation period. Conclusion: In a controlled acute volume overload setting, BNP and NT-proBNP provide comparable information, but their short-term dynamics lag behind clinical decongestion. Routine serial NP measurements at very short time intervals are unlikely to add incremental clinical value in the early phase of acute HF.Keywords
Funding Information
- Abbott Laboratories
This publication has 29 references indexed in Scilit:
- Reduced Congestion and Improved Response to a Fluid/Sodium Challenge in Chronic Heart Failure Patients After Initiation of Sacubitril/Valsartan: The NATRIUM-HF StudyEuropean Journal of Heart Failure, 2024
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart FailureJACC, 2023
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure SocietyEuropean Journal of Heart Failure, 2023
- Biomarkers for the diagnosis and management of heart failureHeart Failure Reviews, 2021
- Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJAMA, 2019
- Sacubitril/Valsartan and B-Type Natriuretic Peptide Value: Recalculating RouteEuropean Journal of Heart Failure, 2019
- Effect of Neprilysin Inhibition on Various Natriuretic Peptide AssaysJACC, 2019
- B-Type Natriuretic Peptide During Treatment With Sacubitril/ValsartanJACC, 2019
- Effects of Sacubitril/Valsartan on Neprilysin Targets and The Metabolism of Natriuretic Peptides in Chronic Heart Failure: A Mechanistic Clinical StudyEuropean Journal of Heart Failure, 2018
- Comparison of the Hydrolysis of the Three Types of Natriuretic Peptides by Human Kidney Neutral Endopeptidase 24.11Biochemical and Molecular Medicine, 1997